Skip to main content
italianoIT
European Commission logo print header

Targeting epigenetic REPROGRamming of innate immune cells in Atherosclerosis Management and other chronic inflammatory diseases

Obiettivo

Up to 70% of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, considered to be incapable of learning ability, does exhibit a memory feature transduced via epigenetic modulation. Compelling evidence shows that atherosclerotic factors promote immune cell migration by pre-activation of innate immune cells. In this project called REPROGRAM, we aim to prove that innate immune cell activation via epigenetic reprogramming perpetuates the upheld systemic inflammatory state in cardiovascular disease which is common in other chronic inflammatory diseases. This opens a new therapeutic area in which epigenetic modulation of innate immune cells effectively decreases systemic inflammation impacting on chronic inflammation as well as the development of co-morbidities. The integrated use of in vitro, ex vivo and in vivo studies, including cells, mice and patients, allows translation from in vitro mechanisms to diseases (molecule-to-man) and extrapolation to cohorts (man-to-mass), enabling us to demonstrate relevance and therapeutic potential of targeting trained immunity in cardiovascular and chronic inflammatory diseases. Enforced by the promising data in oncology, the future prospects for epigenetic interventions in cardiovascular and chronic inflammatory diseases are eminent, attested by the large residual cardiovascular disease burden and the huge societal impact of other chronic inflammatory diseases. The REPROGRAM consortium consisting of key opinion leaders in the field of cardiovascular (systems) biology, immunology, epigenetic therapies and rheumatoid arthritis, with a large intersectoral network, guarantees rapid translation of early mechanistic discoveries

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-PHC-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-PHC-2015-two-stage

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Contribution nette de l'UE
€ 1 112 625,00
Indirizzo
MEIBERGDREEF 15
1105AZ Amsterdam
Paesi Bassi

Mostra sulla mappa
Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 112 625,00

Partecipanti (10)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 13 Settembre 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/667837/it

European Union, 2024